CardioMetabolic Care

Merck Serono combines its drugs for treating diabetes, cardiovascular diseases and thyroid disorders in one therapeutic area: CardioMetabolic Care. In recent years, interrelationships between cardiovascular diseases, diabetes and thyroid disorders have been recognized and documented.
Diabetes and heart disease are closely linked. The frequency of heart attacks (also called myocardial infarction, or MI) is well documented in people with type 2 diabetes. Compared with non-diabetic individuals, those with diabetes are two to three times more likely to have a CV event; moreover, the proportion of people with diabetes who will die from cardiovascular causes is >70%.
Thyroid disorders are also closely associated with both diabetes and cardiovascular disease. In patients with type 2 diabetes, thyroid disorders are two-to-five times more frequent than among the general population. Heart muscle cells contain receptors for thyroid hormones, so cardiac function is influenced by too many or too few thyroid hormones.
Cardiovascular diseases continue to be the most frequent cause of death in industrialized countries. Merck Serono offers an extensive range of therapeutic options to treat these conditions, along with drugs for the treatment of glucose metabolism and thyroid disorders. Merck Serono is among the leading manufacturers of oral antidiabetic agents for the treatment of type 2 diabetes, formerly referred to as “adult-onset diabetes”.

More about:
•    Diabetes
•    Hypertension


Back >>